A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes

NCT05794581 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 1 Diabetes

Interventions

DRUG: CT-868
DRUG: Placebo
DRUG: Victoza

Sponsor

Carmot Therapeutics, Inc.